EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

ILC2s and their immune checkpoints in the antitumor response

Cecilia Ciancaglini, Silvia Santopolo, Paola Vacca, Lorenzo Moretta, Linda Quatrini

Journal for ImmunoTherapy of Cancer · 2026-04 · 14 (4) · e014183

DOI: 10.1136/jitc-2025-014183 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 24.04.2026. Verfasst von Cecilia Ciancaglini und 4 weiteren Autor:innen. Beteiligte Einrichtung: Innate Lymphoid Cell Unit, IRCCS Bambino Gesù Children's Hospital, Rome, Italy. Hauptthemen laut MEDLINE: Neoplasms, Immunity, Innate, Lymphocytes, Immunotherapy. Die Arbeit nennt 127 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Associazione Italiana per la Ricerca sul Cancro, European Union - Next Generation EU - NRRP M6C2 - Investment 2.1 Enhancement and strengthening of biomedical research in the NHS by Italian Ministry of Health, Fondazione Umberto Veronesi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Innate lymphoid cells (ILCs) are tissue-resident lymphocytes that patrol mucosal barriers. Among ILC subsets, ILC2s’ involvement in the innate immune response to parasites, in the development of asthma and in the repair of damaged tissues is well known. However, their role in antitumor immune response is controversial, as it seems to be dependent on the type of cancer and on interaction with the other cell types in the microenvironment. Immune checkpoint expression and function have been studied recently in ILC2s, with a focus on programmed cell death protein-1 (PD-1) and cytotoxic T lymphocyte-associated protein-4 (CTLA-4). This review summarizes recent progress in understanding the ILC2s’ contribution to cancer development and response to immunotherapy targeting inhibitory checkpoints.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsImmunity, InnateLymphocytesImmunotherapyImmune Checkpoint InhibitorsHumansAnimalsTumor Microenvironment

Stichwörter der Autor:innen

ImmunotherapyInnateTumor microenvironment - TME

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Innate Lymphoid Cell Unit, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
  • Tumor Immunology Unit, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
  • Innate Lymphoid Cell Unit, IRCCS Bambino Gesù Children's Hospital, Rome, Italy linda.quatrini@opbg.net.

Förderung

  • Associazione Italiana per la Ricerca sul Cancro
  • European Union - Next Generation EU - NRRP M6C2 - Investment 2.1 Enhancement and strengthening of biomedical research in the NHS by Italian Ministry of Health
  • Fondazione Umberto Veronesi
  • Italian Ministry of Health

Zitieren

APA

Ciancaglini, C., Santopolo, S., Vacca, P., Moretta, L., & Quatrini, L. (2026). ILC2s and their immune checkpoints in the antitumor response. Journal for ImmunoTherapy of Cancer, 14(4), e014183. https://doi.org/10.1136/jitc-2025-014183

Vancouver

Ciancaglini C, Santopolo S, Vacca P, Moretta L, Quatrini L. ILC2s and their immune checkpoints in the antitumor response. Journal for ImmunoTherapy of Cancer. 2026;14(4):e014183. doi:10.1136/jitc-2025-014183

BibTeX
@article{Ciancaglini2026,
  author = {Ciancaglini, Cecilia and Santopolo, Silvia and Vacca, Paola and Moretta, Lorenzo and Quatrini, Linda},
  title = {ILC2s and their immune checkpoints in the antitumor response},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  volume = {14},
  number = {4},
  pages = {e014183},
  doi = {10.1136/jitc-2025-014183}
}
Kostenlos starten →